|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
������� |
|
ҩ���Ʒ�,���� |
|
����ѧ,ҩ�� |
| ��������������� | |
|
��ʫ�� |
|
���� |
| PubMed | |
|
Article by ��ʫ�� |
|
Article by ���� |
�����������������
��ʫ��1, ��ά��2
1. �����еڶ�����ҽԺƤ���� 214000;
2. �й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о���
��һ��ҩ���Ƽ����������ȡ���˽��������Ч,���Դ��ڲ��ֲ�����Ч����,�и������ٸ�Ⱦ�Ŀ���.������ҩ������������������,���ٸ������ٸ�Ⱦ.�������йؿڷ������ÿ����ҩ���������Ƶ��ٴ��о����,�Լ�������Ч���ѡ��������ٸ�Ⱦ�����һЩ����,��������һ�ַ�����Ч���Ѻ��������Ƽ��������ҩ�ﾭ��ѧ����.
1. �����еڶ�����ҽԺƤ���� 214000;
2. �й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о���
1. �����еڶ�����ҽԺƤ���� 214000;
2. �й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о���
[2] Evans EG,Sigurgeirsson B.Double blind,randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis.The LION Study Group.BMJ,1999,318:1031-1035.
[3] Gupta AK,De Doncker P,Scher RK,et al.Itraconazole for the treatment of onychomycosis.Int J Dermatol,1998,37:303-308.
[4] Epstein E.How often does oral treatment of toenail onychomycosis produce a disease-free nail? An analysis of published data.Arch Dermatol,1998,134:1551-1554.
[5] Sigurgeirsson B,Olafsson JH,Steinsson JB,et al.Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis:a 5-year blinded prospective follow-up study.Arch Dermatol,2002,138:353-357.
[6] Soher RK,Baran R.Onychomycosis in clinical practice:factors contributing to recurrence.Br J Dermatol,2003,149:5-9.
[7] Faergemann J,Baran R.Epidemiology,clinical presentation and diagnosis of onychomycosis.Br J Dermatol,2003,149:1-4.
[8] Hay RJ.The future of onychomycosis therapy may involve a combination of approaches.Br J Dermatol,2001,145:3-8.
[9] Olafsson JH,Sigurgeirsson B,Baran R.Combination therapy for onychomycosis.Br J Dermatol,2003,149:15-18.
[10] Evans EG.Drug synergies and the potential for combination therapy in onychomycosis.Br J Dermatol,2003,149:1 1-13.
[11] Arenas R,Fernandez G,Dominguez L.Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent.Int J Dermatol,1991,30:586-589.
[12] Hay RJ,Clayton YM,Moore MK.A comparison of tioconazole 28%nail solution versus base as an adjunct to oral griseofulvin in patients with onychomycosis.Clin Exp Dermatol,1987,12(3):175-177.
[13] Baran R.Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine,a cost-effective treatment for onychomycosis.Br J Dermatol,2001,145:15-19.
[14] Lecha M.Amorolfine and itraconazole combination for severe toenail onychomycosis; results of an open randomized trial in Spain.Br J Dermatol,2001,145:21-26.
[15] Lambert J.Pharmacoeconomic issues in onychomycosis.Br J Dermatol,2003,149:19-22.
[16] Baran R,Feuilhade M,Combernale P,et al.A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region.Br J Dermatol,2000,142:1177-1183.